Skip to main content

Andrew L. Goldberg

Head, Enterprise Technology Development

As the Global Head of Enterprise Technology for AbbVie, a biopharmaceutical biocompany, Andrew leads Enterprise Architecture, Engineering and Operations for infrastructure teams globally and is also responsible for driving automation and innovation. Previously, he held CxO roles at companies including Kemper, Anixter, uBid and Advice America and was a Partner/Managing Director at Deloitte. As a way of giving back to the community, he also has served as Technology Advisor to the Governor of Illinois and helped further the state’s vision of becoming the most high-tech state in the Midwest region.

In this video he talks about:

  • The role automation is playing in AbbVie’s transformation
  • The limitations of automation
  • The affect of COVID-19 on AbbVie’s business
  • The best career advice he has received
  • His technology predictions for 2030.

About AbbVie:

AbbVie is a highly focused research-driven biopharmaceutical company that takes on the toughest health challenges. AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. They strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.